News About: Pharm. Industry
Pharmaceutical patent issue seen as a key FTA agenda
The pharmaceutical patent issues will be resurfaced on the Korea and U.S. free trade agreement (FTA) as a key agenda.
In the seventh round of the FTA talks in Washington DC, the U.S. side will call for their patent...
KPMA protests Korean government's trade-off with US
The Korea Pharmaceutical Manufacturers Association (KPMA) opposed the government's plan for the Korea-U.S. free trade agreement (FTA) that Korea could compromise with the U.S. by giving wider access to Korea's auto an...
Pharmaceutical growth seen slowing in first quarter
Leading pharmaceutical firms' growth in sales is expected to slow further in the first quarter of this year on sluggish domestic demand for prescription drugs, pharmaceutical business sources said.
The downturn of ...
M&A in pharmaceutical industries on rising rumor.
An M&A in the local pharmaceutical industries showed ever rising rumors these days in order to overcome impending environmental challenges stemming from the KORUS FTA, positive list system and massive transfers of dru...
New pharmaceutical industrial part at Jecheon, Choongbuk province.
Following a successful completion of the 1st bio valley project establishment at Jecheon, Choongbuk province, the 2nd bio valley project has been also recently established. At the 1st bio valley industrial park, 65 co...
Dong-A Pharm China as launching pad for pharmaceutical export boostDong-A Pharm is gearing up to make inroads into China to capitalize on the China's growing demand for drugs and consolidate its leadership position in that country.
Dong-A sa...
|
Hanmi ranks 2nd in pharmaceutical sales
Hanmi Pharm ranked second with sales of 422.2 billion won last year, overtaking Yuhan's sales of 411.7 billion won.
Hanmi said on February 5 it posted 422.2 billion won in sales last year, up from 12.1 percent in 2...
AstraZeneca Korea names Lee Won-Kwan new National Sales ManagerAstraZeneca Korea announced recently that it promoted hosptial sales manager Lee Won-Kwan to the post of National Sales Manager in charge of Atacand, one of the popular angioten...
|
Health insurance to exclude Novartis's Sebivo tentatively
The Health Insurance Review Agency (HIRA) plans to exclude Novartis Korea's Sebivo tablet (telbivudine), a new treatment for patients with chronic hepatitis B, from the health insurance list until its price can be lis...
Dong-A achieved great sales at 576,700 MW in 2006.
Dong-A officially disclosed the financial statement of 2006 covering 575,700 MW of sales, 8.1% growth over the previous year and other operating incomes, ordinary incomes and net incomes at 63.8%, 21.4% and 27.2% resp...
